4 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q2
1 Aug 24
to generate innovative and differentiated opportunities and now has over 35 programs in clinical development spanning several distinct therapeutic areas
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
Len covered the status of the Dupixent and itepekimab programs in COPD in great detail, I'd like to start with a bit more about our innovative
REGN
Earnings call transcript
NASDAQ
2023 Q4
2 Feb 24
in 2024 and beyond. Our pipeline of over 30 clinical programs is delivering important and differentiated innovations. Our commercial team is executing well
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
scientific innovations on the horizon.
As Len mentioned, we eagerly await the anticipated approval of aflibercept 8-milligram for retinal diseases
- Prev
- 1
- Next